On March 30, Hana Securities stated that Jetema’s efforts to prepare for the U.S. distribution of Revine and establish local sales capabilities can be viewed as a strategic investment with an eye on the future U.S. entry of The Toxin, for which Phase 2 clinical trials in the U.S. have already been completed.


[Click e-Stock] "Jetema Expands Exports, Diversifies Products, and Enters the U.S. Market" View original image

Da-Hye Kim, a researcher at Hana Securities, said in a report released that day, "In December of last year, the company signed an MOU with Hanmi Pharm to obtain the U.S. sales rights for the skin booster Revine, which repurposes the joint treatment Hyaluma for cosmetic use. Jetema USA plans to market Revine primarily through the Medspa channel in the U.S., with the expected launch scheduled for the third quarter of this year." She added, "In addition to Hanmi Pharm’s skin booster, the company is also considering the domestic distribution of an extracellular matrix (ECM) skin booster to diversify its product lineup."


Jetema is a comprehensive aesthetics company manufacturing and selling various medical beauty products such as botulinum toxin, hyaluronic acid fillers, and lifting threads. It was founded in 2009 by co-CEOs Jaeyoung Kim and Jungseon Nam. Jetema’s botulinum toxin product, The Toxin, is notable for being manufactured from a strain formally adopted by a UK national institution in 2017, providing clear traceability of its source. In 2025, Jetema recorded consolidated revenue of 7.69 billion won, operating profit of 380 million won, and net profit attributable to controlling shareholders of negative 670 million won (a turnaround to a deficit).



Researcher Kim commented, "The biggest concern for investors, the overhang risk, is expected to be resolved with the maturity of convertible bonds on July 6. The company is preparing for repayment by promoting the sale of its headquarters building, and after maturity, the derivative valuation losses associated with the convertible bonds will be eliminated. This should allow for a turnaround not only in operating profit but also in net profit."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing